These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34298576)

  • 21. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.
    Huang H; Li CQ; He DN; Ruan SM; Li MD; Cheng MQ; Lu MD; Kuang M; Wang W; Wang Y; Chen LD
    Eur Radiol; 2023 Dec; 33(12):9336-9346. PubMed ID: 37405501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
    Santillan C; Fowler K; Kono Y; Chernyak V
    Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein.
    Jiang ZP; Zeng KY; Huang JY; Yang J; Yang R; Li JW; Qiu TT; Luo Y; Lu Q
    World J Gastroenterol; 2022 Jun; 28(21):2350-2360. PubMed ID: 35800178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrast-enhanced ultrasound algorithm (ACR CEUS LI-RADSv 2017)- a valuable tool for the noninvasive diagnosis of hepatocellular carcinoma in patients with chronic liver disease.
    Ghiuchici AM; Dănilă M; Popescu A; Șirli R; Moga T; Topan M; Bende F; Sporea I
    Med Ultrason; 2021 Nov; 23(4):383-389. PubMed ID: 33793696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
    Yang D; Hu H; Li R; Tang CL; Ma KS; Guo DY
    Abdom Radiol (NY); 2022 Feb; 47(2):630-639. PubMed ID: 34910237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
    Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
    Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Time Difference Method in Identifying Hepatocellular Carcinoma in Current CEUS LR-M Category Nodules.
    Shao LJ; Wang YJ; Yin SS; Jiang BB; Liu YH; Wang JC; Yang W; Wu W; Yan K
    Ultrasound Med Biol; 2024 Apr; 50(4):502-508. PubMed ID: 38246805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nodules Identified on Surveillance Ultrasound for HCC: CEUS or MRI as the Initial Test?
    Hu J; Burrowes DP; Caine BA; Gibson N; Bhayana D; Medellin A; Burak KW; Wilson SR
    J Ultrasound Med; 2023 Jun; 42(6):1181-1190. PubMed ID: 36807925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Contrast-enhanced ultrasound: Liver Imaging Reporting and Data System (CEUS LI-RADS)].
    Dietrich CF; Potthoff A; Helmberger T; Ignee A; Willmann JK;
    Z Gastroenterol; 2018 May; 56(5):499-506. PubMed ID: 29734449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.
    Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH
    Front Oncol; 2021; 11():641195. PubMed ID: 33912456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of CT/MRI LI-RADS with CEUS can improve the diagnostic performance for HCCs.
    Zhou Y; Ding J; Qin Z; Long L; Zhang X; Wang F; Chen C; Wang Y; Zhou H; Jing X
    Eur J Radiol; 2022 Apr; 149():110199. PubMed ID: 35196614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5).
    Terzi E; Giamperoli A; Iavarone M; Leoni S; De Bonis L; Granito A; Forgione A; Tovoli F; Piscaglia F
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm.
    Ronot M; Fouque O; Esvan M; Lebigot J; Aubé C; Vilgrain V
    J Hepatol; 2018 Apr; 68(4):715-723. PubMed ID: 29274407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
    Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
    Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LI-RADS: Past, Present, and Future, From the
    Marks RM; Masch WR; Chernyak V
    AJR Am J Roentgenol; 2021 Feb; 216(2):295-304. PubMed ID: 33052720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations.
    Arvind A; Joshi S; Zaki T; Burkholder D; Parikh ND; Singal AG;
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1091-1093.e3. PubMed ID: 34902571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular Carcinoma in Evolution: Correlation with CEUS LI-RADS.
    Nguyen SA; Merrill CD; Burrowes DP; Medellin GA; Wilson SR
    Radiographics; 2022; 42(4):1028-1042. PubMed ID: 35486579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
    Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
    Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.